Digitizing the Genome: Enabling New Models for Population-Scale Genomics

[Available On-Demand] ・ Click video to start playback;Join chat Q&A below video
Search General Info
Genomics is at an inflection point. Dramatic declines in the cost of sequencing combined with significant advances in our understanding of the genome mean that we can now offer researchers deeper insights into more aspects of the genome than ever before. But traditional approaches to leveraging this data have limitations - the data is often siloed within individual institutions, not paired with deep phenotypic data, and requires large-scale compute infrastructure to analyze. Learn how health systems, life sciences companies, and payers are working together to address these obstacles and use “digitized” genomics to accelerate drug discovery, development, and commercialization – and to improve outcomes for patients.
Moderator
photo
Partner
Cooley
Speakers
photo
Chief Scientific Officer; Director
Renown Health; Renown Institute for Health Innovation
photo
Executive Director, Head of Emerging Portfolio, Emerging Science & Innovation
Pfizer
photo
Co-Founder & Chief Scientific Officer
Helix
photo
Partner
Cooley